Determining hypoxic fraction in a rat glioma by uptake of radiolabeled fluoromisonidazole

Radiation Research

Volumn 153, Issue 1, 2000, Pages 84-92

  Rasey, Janet S ^a   Casciari, Joseph J ^a   Hofstrand, Philip D ^a   Muzi, Mark ^a   Graham, Michael M ^a   Chin, Lay K ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MISONIDAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; BRAIN HYPOXIA; CELL PROTECTION; CONTROLLED STUDY; DRUG DETERMINATION; DRUG UPTAKE; GLIOMA; IMAGE ANALYSIS; ISOTOPE LABELING; MATHEMATICAL MODEL; NONHUMAN; OXYGEN BLOOD LEVEL; PRIORITY JOURNAL; RADIATION RESPONSE; RAT;

EID: 0033995078     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/0033-7587(2000)153[0084:DHFIAR]2.0.CO;2     Document Type: Article

References (51)

1. J. D. Chapman, Hypoxic sensitizers - implications for radiation therapy. N. Engl. J. Med. 301, 1429-1432 (1979).
2. J. D. Chapman, A. J. Franko and J. Sharplin, A marker for hypoxic cells in tumours with potential clinical applicability. Br. J. Cancer 43, 546-550 (1981).
3. R. J. Hodgkiss, L. Webster and G. D. Wilson, Development of bioreductive markers for tumour hypoxia. Acta Oncol. 34, 351-355 (1995).
4. D. Groshar, A. J. McEwan, M. B. Parliament, R. C. Urtasun, L. E. Golberg, M. Hoskinson, J. R. Mercer, R. H. Mannan, L. I. Wiebe and J. D. Chapman, Imaging tumor hypoxia and tumor perfusion. J. Nucl. Med. 34, 885-888 (1993).
5. J. S. Rasey, Z. Grunbaum, S. Magec, N. J. Nelson, P. Olive, R. Durand and K. A. Krohn, Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiat. Res. 111, 292-304 (1987).
6. J. S. Rasey, W. J. Koh, J. R. Grierson, Z. Grunbaum and K. A. Krohn, Radiolabeled fluoromisonidazole as an imaging agent for tumor hypoxia. Int. J. Radiat. Oncol. Biol. Phys. 17, 985-991 (1989).
7. J. S. Rasey, N.J. Nelson, L. Chin, M. L. Evans and Z. Grunbaum, Characterization of the binding of labeled fluoromisonidazole in cells in vitro. Radiat. Res. 122, 301-308 (1990).
8. W. J. Koh, J. S. Rasey, M. L. Evans, J. R. Grierson, T. K. Lewellen, M. M. Graham, K. A. Krohn and T. W. Griffin, Imaging of hypoxia in human tumors with (F-18]fluoromisonidazole. Int. J. Radiat. Oncol. Biol. Phys. 22, 199-212 (1992).
9. W. J. Koh, K. S. Bergman, J. S. Rasey, L. M. Peterson, M. L. Evans, M. M. Graham, J. R. Grierson, T. K. Lewellen, K. A. Krohn and T. W. Griffin, Evaluation of oxygenation status during fractionated radiotherapy in human non-small cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int. J. Radiat. Oncol. Biol. Phys. 33, 391-398 (1995).
10. J. M. Cline, D. E. Thrall, G. L. Rosner and J. A. Raleigh, Distribution of the hypoxia marker CCI-103F in canine tumors. Int. J. Radiat. Oncol. Biol. Phys. 28, 921-933 (1994).
11. E. M. Lord, L. Harwell and C. J. Koch, Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Res. 53, 5271-5276 (1993).
12. J. A. Raleigh, J. K. La Dine, J. M. Cline and D. E. Thrall, An enzyme-linked immunosorbent assay for hypoxia marker binding in tumours. Br. J. Cancer 69, 66-71 (1994).
13. 18F]fluoromisonidazole: A pretherapy study of 37 patients. Int. J. Radiat. Oncol. Biol. Phys. 36, 417-428 (1996).
14. 3H]fluoromisonidazole uptake data. Radiat. Res. 141, 28-36 (1995).
15. J. R. Grierson, C. A. Mathis, J. S. Rasey and K. A. Krohn, A radiosynthesis of fluorine 18 fluoromisonidazole. J. Nucl. Med. 30, 343-350 (1989).
16. J. E. Moulder and S. Rockwell, Hypoxic fractions of solid tumors: Experimental techniques, methods of analysis, and a survey of existing data. Int. J. Radiat. Oncol. Biol. Phys. 10, 695-712 (1984).
17. J. J. Casciari, M. M. Graham and J. S. Rascy, A modeling approach for quantifying tumor hypoxia with [F-18]fluoromisonidazole PET time-activity data. Med. Phys. 22, 1127-1139 (1995).
18. H. W. Chalkey, Method for quantitative morphologic analysis of tissues. J. Natl. Cancer Inst. 4, 47-53 (1943).
19. E. J. Hall, Radiobiology for the Radiologist, 4th ed. J. B. Lippincott, Philadelphia, 1994.
20. L. M. Van Putten and R. F. Kallman, Oxygenation status of a transplantable tumor during fractionated radiation therapy. J. Natl. Cancer Inst. 40, 441-451 (1968).
21. J. D. Chapman, K. Baer and J. Lee, Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells. Cancer Res. 43, 1523-1528 (1983).
22. 14C-misonidazole in multicell spheroids. Radiat Res. 101, 473-479 (1985).
23. A. J. Franko, Misonidazole and other hypoxia markers: Metabolism and applications. Int. J. Radiat. Oncol. Biol. Phys. 12, 1195-1202 (1986).
24. J. M. Brown, Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. Br. J. Radiol. 52, 650-656 (1979).
25. C. N. Coleman, Hypoxia in tumors: A paradigm for the approach to biochemical and physiologic heterogeneity. J. Natl. Cancer Inst. 80, 310-317 (1988).
26. H. Kimura, R. D. Braun, E. T. Ong, R. Hsu, T. W. Secomb, D. Papahadjopoulos, K. Hon and M. W. Dewhirst, Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res. 56, 5522-5528 (1996).
27. J. D. Chapman, R. C. Urtasun, A. J. Franko, J. A. Raleigh, B. E. Meeker and S. A. McKinnon, The measurement of oxygenation status of individual tumors. In Prediction of Response in Radiation Therapy: The Physical and Biological Basis (B. R. Paliwal, J. F. Fowler D. E. Herbert, T. J. Kinsella and C. G. Orton, Eds.), pp. 49-60. American Institute of Physics, New York, 1989.
28. C. J. Koch, The reduction activation of nitroimidazoles; modification by oxygen and other redox-active molecules in cellular systems. In Selective Activation of Drugs by Redox Processes (G. E. Adams, Ed.), pp. 237-247. Plenum Press, New York, 1990.
29. B. G. Wouters and J. M. Brown, Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy. Radiat. Res. 147, 541-550 (1997).
30. M. R. Horsman, A. A. Khalil, D. W. Siemann, C. Grau, S. A. Hill, E. M. Lynch, D. J. Chaplin and J. Overgaard, Relationship between radiobiological hypoxia in tumors and electrode measurements of tumor oxygenation. Int. J. Radiat. Oncol. Biol. Phys. 29, 439-442 (1994).
31. M. Nordsmark, C. Grau, M. R. Horsman, H. S. Jorgensen and J. Overgaard, Relationship between tumour oxygenation, bioenergetic status and radiobiological hypoxia in an experimental model. Acta Oncol. 34, 329-334 (1995).
32. 3H]misonidazole binding and paired survival assay. Radiat. Res. 145, 491-500 (1996).
33. D. M. Brizel, G. S. Sibley, L. R. Prosnitz, R. L. Scher and M. W. Dewhirst, Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 38, 285-289 (1997).
34. R. A. Gatenby, H. B. Kessler, J. S. Rosenblum, R. Cola, P. J. Moldofsky, W. H. Hartz and G. J. Broder, Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 14, 831-838 (1988).
35. M. Hockel, B. Vorndran, K. Schlenger, E. Baussmann and P. G. Knapstein, Tumor oxygenation: A new predictive parameter in locally advanced cancer of the uterine cervix. Gynecol. Oncol. 51, 141-149 (1993).
36. P. Kolstad, Intercapillary distance, oxygen tension, and local recurrence in cervical cancer. Scand. J. Clin. Lab. Invest. 106 (Suppl.), 145-157 (1968).
37. M. Nordsmark, M. Overgaard and J. Overgaard, Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother. Oncol. 41, 31-39 (1996).
38. J. M. Cline, G. L. Rosner, J. A. Raleigh and D. E. Thrall, Quantification of CCI-103F labeling heterogeneity in canine solid tumors. Int. J. Radiat. Oncol. Biol. Phys. 37, 655-662 (1997).
39. A. S. Kennedy, J. A. Raleigh, G. M. Perez, D. P. Calkins, D. E. Thrall, D. B. Novotny and M. A. Varia, Proliferation and hypoxia in human squamous cell carcinoma of the cervix: First report of combined immunohistochemical assays. Int. J. Radiat. Oncol. Biol. Phys. 37, 897-905 (1997).
40. R. J. Hodgkiss, Use of 2-nitroimidazoles as bioreductive markers for tumour hypoxia. Anti-Cancer Drug Des. 13, 687-702 (1998).
41. M. A. Varia, D. P. Calkins, L. H. Rinker, A. S. Kennedy, D. B. Novotny, W. C. Fowler, Jr. and J. A. Raleigh, Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecol. Oncol. 71, 270-277 (1998).
42. J. A. Raleigh, D. P. Calkins, L. H. Rinker, C. A. Ballenger, M. C. Weissler, W. C. Fowler, Jr., D. B. Novotny and M. A. Varia, Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Res. 58, 3765-3768 (1998).
43. J. A. Raleigh, C. S. Chou, G. E. Arteel and M. R. Horsman, Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. Radiat. Res. 151, 580-589 (1999).
44. H. Lyng, K. Sundfor and E. K. Rofstad, Oxygen tension in human tumours measured with polarographic needle electrodes and its relationship to vascular density, necrosis, and hypoxia. Radiother. Oncol. 44, 163-169 (1997).
45. M. Nozue, I. Lee, F. Yuan, B. A. Teicher, D. M. Brizel, M. W. Dewhirst, C. G. Milross, L. Milas, C. W. Song and H. D. Suit, Interlaboratory variation in oxygen tension measurement by Eppendorf "Histograph" and comparison with hypoxic marker. J. Surg. Oncol. 66, 30-38 (1997).
46. K. Sasai and J. M. Brown, Discrepancies between measured changes of radiobiological hypoxic fraction and oxygen tension monitoring using two assay systems. Int. J. Radiat. Oncol. Biol. Phys. 30, 355-361 (1994).
47. I. H. Kim, M. J. Lemmon and J. M. Brown, The influence of irradiation of the tumor bed on tumor hypoxia: Measurements by radiation response, oxygen electrodes, and nitroimidazole binding. Radiat Res. 135, 411-417 (1993).
48. D. G. Hirst, J. L. Hazlehurst and J. M. Brown, Changes in misonidazole binding with hypoxic fraction in mouse tumors. Int. J. Radiat. Oncol. Biol. Phys. 11, 1349-1355 (1985).
49. R. H. Mannan, V. V. Somayaji, J. Lee, J. R. Mercer, J. D. Chapman and L. I. Wiebe, Radioiodinated 1-(5-iodo-5-deoxy-β-D-arabinofuranosyl)-2-nitroimidazole (iodoazomycin arabinoside: IAZA): A novel marker of tissue hypoxia. J. Nucl. Med. 32, 1764-1770 (1991).
50. 123I]iodoazomycin arabinoside: preliminary report of a clinical study. Br. J. Cancer 65, 90-95 (1992).
51. 3H-labelled misonidazole in the tumor-bearing mouse. Int. J. Radiat. Oncol. Biol. Phys. 18, 347-351 (1990).